Please assess the completion status of the following clinical trial:

Trial Title: Application of Convalescent Plasma in the Treatment of SARS CoV-2 Disease (COVID-19) With Evaluation of Therapy Effectiveness

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~Donors:~1. Age \>18 and \<65 years~2. Confirmed previous SARS CoV-2 infection~3. Signed informed consent to participate in this clinical trial, to donate plasma and to store the specimen for future testing.~4. At least 28 days from the end of isolation or resolution of symptoms of infection~5. Male donors, or female donors who have not been pregnant, or female donors who have been pregnant tested negative for HLA antibodies~6. Individuals who meet all regular voluntary donor eligibility requirements~Recipiants:~1. Signed informed consent to participate in this clinical trial.~2. Confirmed previous SARS CoV-2 infection~3. Respiratory distress with tachypnoe ≥30 breaths per minute,~4. Oxygen level less than 94% in resting-state,~5. Partial pressure of oxygen (PO2) ≤ 80 mmHg~Exclusion Criteria:~Donors:~1. Age : \<18 or \>65 years~2. Female subjects who are pregnant~3. HIV1,2 hepatitis B,C or syphilis infection~4. Donors ineligible for regular voluntary blood donation~Recipiants:~1. No informed consent to participate in the study~2. Patients with a history of plasma hypersensitivity, including anaphylactic shock in previous transfusions, allergic reactions to citrate or primary IgA deficiency~3. Patients with symptoms of severe multi-organ failure~4. Patients with known allergic reactions to chemical compounds used or generated in the procedure of inactivation of pathogens~5. Patients with active thrombosis

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Hospitalized patients with SARS CoV-2 infection (Type: EXPERIMENTAL): Hospitalized patients with SARS CoV-2 infection will receive an anti SARS-CoV-2 convalescent plasma

Based on this trial design, predict the completion outcome and termination type (if applicable).